Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 0%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte is a genomic diagnostics company that is a leader in the growing market for next-generation diagnostic tests. With an expanding portfolio of advanced diagnostic tests, Veracyte is well positioned for sustained revenue growth. The recent acquisition of C2i Genomics and its minimal residual disease test for muscle-invasive bladder cancer further strengthens their position in the market. Additionally, the company's plans to launch kitted versions of their tests and expand internationally are expected to drive growth. With strong double digit growth and a unique competitive advantage in leveraging their broad urology sales channel, Veracyte has a positive outlook from a financial analyst's perspective.

Bears say

Veracyte is currently facing strong headwinds in revenue growth, with its most recent quarter only seeing an 18.5% increase in revenue, below both its own preannouncement and analyst consensus. Its recent entrance into the MRD market with the TrueMRD platform may be overshadowed by competition from other companies with similar offerings, and its projected opportunity in bladder cancer is relatively small at $200M. With a negative outlook for revenue and earnings growth, it may be difficult for Veracyte to meet its ambitious revenue and margin targets, resulting in a bear case valuation of ~$24 per share.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.